𝗔𝗜 + 𝗛𝗧-𝗦𝗣𝗥 = 𝗔 𝗡𝗲𝘄 𝗘𝗿𝗮 𝗼𝗳 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆! Carterra is thrilled to partner with innovators at the forefront of drug discovery. 𝗢𝗻𝗲 𝗵𝗼𝘁 𝘁𝗼𝗽𝗶𝗰: 𝗵𝗼𝘄 𝗔𝗜 𝗶𝘀 𝗿𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝗲𝗮𝗿𝗰𝗵 𝗳𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱, 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀— 𝗮𝗻𝗱 𝗔𝗯𝘀𝗰𝗶 𝗶𝘀 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗵𝗮𝗿𝗴𝗲. ✨ Check out the latest feature in the International Biopharmaceutical Industry's Autumn 2024 issue to see how Carterra’s HT-SPR technology is helping Absci validate AI models and accelerate high-throughput lead optimization. https://lnkd.in/d5s_wxhN #DrugDiscovery #AI #Biotech #Innovation #HTSPR #LSA #Absci
Carterra
Biotechnology
Salt Lake City, UT 6,450 followers
High-throughput SPR technology for antibody and drug discovery enabling fast candidate selection
About us
Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com
- Website
-
https://www.carterra-bio.com
External link for Carterra
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Salt Lake City, UT
- Type
- Privately Held
- Founded
- 2005
- Specialties
- biotechnology, antibody discovery, label-free, epitope binning, kinetic characterization, SPR, epitope mapping, cancer, neuroscience, infectious disease, immunooncology, antibody development, B-Cell Enrichment, phage display, protein-protein, hybridoma , B Cell Cloning , covid19, immunity monitoring , vaccine research , serology , and hybridoma screening
Locations
Employees at Carterra
Updates
-
Join Xavier PIERRAT’s talk at Festival of Biologics 𝘁𝗼𝗱𝗮𝘆, which will discuss how the Carterra LSA at IGI is advancing polyreactivity measurements, enabling the fast selectivity of developable candidates.
Proud to join 350+ expert speakers at Festival of Biologics Basel 2025! Contributing to conversations shaping the future of antibody therapies, CGTs, and more. #FestivalOfBiologics At Ichnos Glenmark Innovation (IGI), we leverage our proprietary BEAT® heterodimerization platform to generate multispecific antibodies for the clinic. This talk focuses on the efforts to generate highly developable candidates to maximize the therapeutic window for the benefits of patients. In particular, I will describe a high-throughput polyreactivity screening method by SPR that we developed internally using the LSA (Carterra).
-
-
Joining Festival of Biologics in Basel? Pfizer and Carterra came together to showcase our high-throughput SPR workflow that uncovers antibody pairs that traditional ELISAs overlook. Find us together at 𝘀𝘁𝗮𝗻𝗱 𝟱𝟬𝟯𝗖 with our collaborator, AVS Bio (previously IPA Europe). Andrew Goodhead Ilse Roodink, Ph.D. Edward Verwayen Nienke Smits #drugdiscovery #biologics #highthroughput #SPR #antibodies #collaborate
-
-
Headed to 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗼𝗻 𝗧𝗮𝗿𝗴𝗲𝘁 𝗶𝗻 𝗕𝗼𝘀𝘁𝗼𝗻? Don’t miss these two posters highlighting how Carterra's HT-SPR technology accelerates PROTAC characterization and high-throughput kinase fragment screening. Carterra will be at 𝗕𝗼𝗼𝘁𝗵 𝟮𝟬𝟳 — come see us! #DrugDiscovery #BostonDOT #biotechnology #pharma #biopharma #research #science
-
-
Jon Popplewell, PhD will present a poster at FBLD Conference 2025 on how Carterra's high-throughput SPR technology enabled screening of 100k+ fragment/protein interactions in just days — delivering faster, broader, and more precise insights. Visit us at Stand 4 to discover how our platforms are accelerating hit-to-lead decisions with unprecedented scale and precision. #DrugDiscovery #SPR #Proteomics #FBLD2025 #BiotechInnovation #Fragments
-
-
Ready to take your SPR skills to the next level? Join Carterra’s SPR Camp and learn directly from the experts! Walnut Creek, CA – October 28–29 Cambridge, UK – March 3–4, 2026 Seats are limited, so don’t wait—secure your spot today and become an SPR pro! Register here: https://lnkd.in/g2PrurCy #SPR #training #drugdiscovery #labskills
-
-
Carterra is thrilled to join the 5th International Antibody Validation Meeting! With a program full of groundbreaking science, don’t miss the talks from Andrew Bradbury (Specifica, an IQVIA business) and Deborah Moshinsky (Institute for Protein Innovation) as they showcase how HT-SPR is transforming antibody and reagent qualification and validation, shaping the future of drug discovery. #AntibodyValidation #DrugDiscovery #SPR #Carterra #AbVal25
-
-
HT-SPR is revolutionizing biologics discovery. ACROBiosystems' recent webinar featuring our very own Daniel Bedinger, Sr. Manager of Field Application Science, does a nice job of explaining how. 🧬𝗦𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗔𝗰𝘁𝗶𝘃𝗶𝘁𝘆 – Measure binding vs. protein content 🧬𝗣𝗼𝗹𝘆𝗿𝗲𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆 – Screen large candidate/target sets 🧬𝗘𝗽𝗶𝘁𝗼𝗽𝗲 𝗕𝗶𝗻𝗻𝗶𝗻𝗴 – Rapidly ID immunoassay pairs Check out the discussion here: https://lnkd.in/ea569VBm #HTSPR #Biologics #DrugDiscovery #Immunoassays #ACROBiosystems #Carterra
-
-
Carterra is made for AI and vice versa. There is no other binding analysis platform that can generate enough data in early drug discovery to train AI algorithms. Hear how we do it as Tim Germann, Carterra’s CCO, discusses this with industry vet Rizwan Chaudhrey. #AI #DrugDiscovery #Carterra #SPR #MachineLearning
-
We’re proud to announce the publication of a new 𝗽𝗲𝗲𝗿-𝗿𝗲𝘃𝗶𝗲𝘄𝗲𝗱 𝗯𝗼𝗼𝗸 𝗰𝗵𝗮𝗽𝘁𝗲𝗿 𝗼𝗻 𝗲𝗽𝗶𝘁𝗼𝗽𝗲 𝗯𝗶𝗻𝗻𝗶𝗻𝗴 𝗶𝗻 𝙀𝙥𝙞𝙩𝙤𝙥𝙚 𝙈𝙖𝙥𝙥𝙞𝙣𝙜 𝙋𝙧𝙤𝙩𝙤𝙘𝙤𝙡𝙨 𝗯𝘆 Springer Nature — authored by our very own Carterra scientists. Meaningful epitope binning can only be achieved using Carterra’s platform and is essential for drug discovery, helping scientists map antibody diversity, identify lead candidates, and accelerate development. Read it here: https://lnkd.in/dQUqsAR3 #Carterra #EpitopeBinning #AntibodyDiscovery #DrugDiscovery #HTSPR #Biotech #SpringerNature
-